In refractory leukemia, IV busulfan plus cyclophosphamide may be a valid alternative
the ONA take:
Intravenous busulfan plus cyclophosphamide may be a valid and efficient alternative to cyclophosphamide plus total body irradiation conditioning regimen for patients with refractory acute myeloid leukemia, according to a new study published online ahead of print in the The Lancet Haematology.
For the study, researchers analyzed data from 514 patients with refractory acute myeloid leukemia in active phase who had received intravenous busulfan plus cyclophosphamide and 338 patients who had received cyclophosphamide plus total body irradiation. All patients then received allogenic hematopoietic stem-cell transplantation from an HLA-identical sibling or an unrelated donor.
Results showed that 2-year overall survival and 2-year leukemia-free survival did not differ between the 2 groups. Researchers found that the main reasons for non-relapse mortality were graft-versus-host disease and infection.
The findings suggest that intravenous busulfan plus cyclophosphamide may be especially preferable for transplant centers that do not have access to radiation facilities.
Intravenous busulfan plus cyclophosphamide may be a valid and efficient alternative for patients with refractory acute myeloid leukemia.
- Sexual Dysfunction in Women With Cancer: A Review of Available Interventions
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
- Affect of Daratumumab on Laboratory Blood Test Results
- Geriatric Consults Rare in Kidney Cancer Care
- Worse Survival Seen for Alternative Versus Usual Cancer Therapy
- Anorexia-Cachexia in Non-Small Cell Lung Cancer Improved With Anamorelin
- Early Recognition of Checkpoint Inhibitor-Related Pneumonitis Improves Outcomes
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|